LATEST
Maximus Federal Services agreed to acquire Agile DefensenewMount Logan Management agreed to acquire Alternative Fund AdvisorsnewDime Commercial Bancshares / ES BancsharesnewSalesforce agreed to acquire BrazeJV Investors / Oro Mobility HoldingsMorgan Stanley Capital Partners acquired The Rapid GroupCBRE Group agreed to acquire Onnec GroupBevPoint Capital agreed to acquire ESGMarwynn Holdings acquired Zhituo SoftwareAspire-Lakewood Holding acquired Dura Driver Control SystemsSilgan / Trivium: minority stakeBF International Best Fields Best Food / Diagram
Open App
Agreement signedAgreed 2 Oct 2023

Eli Lilly and Company /
POINT Biopharma Global Inc.

Eli Lilly and Company agrees to buy POINT Biopharma Global Inc.

Buy side: Eli Lilly and Company
Buy sideEli Lilly and Company
Target: POINT Biopharma Global Inc.
TargetPOINT Biopharma Global Inc.
Source · 2 Oct 2023
See the source
Buy side: Eli Lilly and Company
Buy sideEli Lilly and Company
Target: POINT Biopharma Global Inc.
TargetPOINT Biopharma Global Inc.
01 / BuyerEli Lilly and Company
02 / TargetPOINT Biopharma Global Inc.
01

What happened

Eli Lilly and Company agreed to acquire POINT Biopharma Global Inc. for $12.50 per share, according to a filing dated Dec. 27, 2023.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Eli Lilly and Company agrees to buy POINT Biopharma Global Inc.

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

  2. Announced

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.